New drug therapy for low cardiac output syndrome after congenital heart disease surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040608

Enrollment

Unknown

Registered

2020-12-03

Start date

2020-11-20

Completion date

Unknown

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low cardiac output syndrome

Interventions

Traditional vasoactive drugs +levosimendan group:use traditional vasoactive drugsand levosimendan

Traditional vasoactive drugs group:use traditional vasoactive drugs

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Aged 0-18 years old children with congenital heart disease after biventricular correction, CI =10.

Exclusion criteria

Exclusion criteria: Single ventricle, cardiomyopathy, midway death or voluntary withdrawal, severe hypotension (blood pressure lower than 30% of the lower limit of the same age group).

Design outcomes

Primary

Measure	Time frame
Left ventricular ejection fraction;cardiac index;	—

Secondary

Measure	Time frame
Left ventricular end diastolic diameter;Left ventricular end systolic diameter;Systemic vascular resistance index;systolic pressure;heart rate;vasoactive-inotropic score;NT-proBNP;	—

Countries

China

Contacts

Public ContactWei Dan

Children's Hospital Affiliated to Capital Institute of Pediatrics

cristwyd@163.com+86 13651241331

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026